|
Targeting B-cell lymphoma with Leukothera
|
3R41CA173900-01S1
|
$108,255
|
Belinka, Benjamin
|
ACTINOBAC BIOMED, INC.
|
|
Minimal Residual Disease Monitoring by T-cell Receptor Repertoire Profiling
|
1R43CA167972-01A1
|
$165,191
|
RIEDER, MARK
|
ADAPTIVE TCR CORPORATION
|
|
Core Support for Cancer Center
|
2P30CA013330-40
|
$3,589,611
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Core Support for Cancer Center
|
3P30CA013330-40S1
|
$75,000
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Somatic Mutation of IG Variable Regions
|
5R01CA072649-15
|
$371,121
|
SCHARFF, MATTHEW
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Mismatch repair in V region mutation and isotype switching
|
5R01CA102705-10
|
$296,012
|
SCHARFF, MATTHEW
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
EASTERN COOPERATIVE ONCOLOGY GROUP
|
3U10CA014958-38S1
|
$144,167
|
Sparano, Joseph
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-24
|
$486,165
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
SPORE in Lymphoma
|
5P50CA126752-07
|
$2,150,500
|
Heslop, Helen
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-07S1
|
$75,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-07S2
|
$43,265
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-07
|
$3,092,811
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Engineered tumor-specific T cells Resist Hypoxic-Tumor Immunosuppressive Attacks.
|
5R01CA142664-04
|
$290,421
|
YOTNDA, PATRICIA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Eastern Cooperative Oncology Group
|
3U10CA080775-14S1
|
$43,980
|
BUBLEY, GLENN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Lig4R278H contribution to HSC and IgH class switching defects and malignancies
|
1R01CA161151-01A1
|
$361,048
|
Yan, Catherine
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Cancer and Leukemia Group B CCOP Research Base
|
3U10CA037447-28S1
|
$362,418
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B
|
5U10CA031946-32
|
$9,816,255
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B CCOP Research Base
|
5U10CA037447-29
|
$2,684,982
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
A prospective analysis of peripheral blood cytokines and non-Hodgkin lymphoma
|
5R01CA149445-03
|
$560,228
|
BIRMANN, BRENDA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Genetic and Proteomic Analysis of Epstein-Barr Virus LMP1 Activation of NF-kB
|
5K08CA140780-04
|
$179,910
|
Gewurz, Benjamin
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Roles of Epstein-Barr virus nuclear antigens 2 and LP in B cell proliferation
|
1R01CA170023-01A1
|
$365,632
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Epstein-Barr Virus Nuclear Protein in B Cell Growth Transformation
|
5R01CA047006-26
|
$531,318
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Epstein-Barr Virus LMP1-Mediated Oncogenecity
|
5R01CA085180-12
|
$659,320
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Inhibitors of Epstein-Barr Virus Nuclear Protein 1 Mediated Latent Infection
|
5R01CA131354-05
|
$337,720
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Development of Therapeutic CD59 inhibitor for treating B-cell malignancies
|
1R01CA166144-01A1
|
$119,146
|
Qin, Xuebin
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Drug candidates that disrupt the NEMO/IKK signaling complex for the treatment of
|
2R44CA153676-02
|
$987,616
|
Hansen, Stig
|
CARMOT THERAPEUTICS, INC.
|
|
Eastern Cooperative Oncology Group Studies
|
3U10CA014548-38S1
|
$334,918
|
AVERBOOK, BRUCE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Bcl-2 function on the endoplasmic reticulum
|
5R01CA085804-14
|
$267,381
|
DISTELHORST, CLARK
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
|
3U01CA062502-19S1
|
$841,154
|
DOWLATI, AFSHIN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
2P30CA043703-23
|
$4,740,480
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-23S2
|
$37,026
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
SBIR Phase II Topic 307: Monitoring Anticancer Immune Response Non-Invasively wit
|
N44CO130063-000
|
$1,499,971
|
YAGHOUBI, SHAHRIAR
|
CELLSIGHT TECHNOLOGIES, INC.
|
|
RhoH GTPase in Hematopoiesis and Cancer
|
5R01CA113969-09
|
$306,016
|
WILLIAMS, DAVID
|
CHILDREN'S HOSPITAL CORPORATION
|
|
Molecular Programs for Stem Cells of Hematological Malignancies
|
7R21CA164469-02
|
$175,827
|
Wang, Yin
|
CHILDREN'S RESEARCH INSTITUTE
|
|
Delaware/Christiana Care Community Clinical Oncology Program
|
5U10CA045418-27
|
$1,543,934
|
Grubbs, Stephen
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
Anthraycline-related cardiotoxicity in long-term survivors of lymphoma
|
1R21CA178344-01
|
$189,963
|
ARMENIAN, SARO
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Research and Mentoring on Energetic Factors and Cancer: Established Investigator
|
5K05CA136967-05
|
$139,821
|
BERNSTEIN, LESLIE
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
City of Hope Lymphoma SPORE
|
5P50CA107399-08
|
$2,150,500
|
Forman, Stephen
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
2P30CA033572-30
|
$2,042,489
|
FRIEDMAN, MICHAEL
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-30S1
|
$125,000
|
FRIEDMAN, MICHAEL
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-30S2
|
$52,354
|
FRIEDMAN, MICHAEL
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cancer Center Support Grant
|
3P30CA033572-30S3
|
$10,680
|
FRIEDMAN, MICHAEL
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
City of Hope Southwest Oncology Group Clinical Trials
|
5U10CA046368-26
|
$340,319
|
MORTIMER, JOANNE
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Phase I Molecular and Clincal Pharmacodynamic Trials
|
3U01CA062505-19S1
|
$590,190
|
NEWMAN, EDWARD
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Molecular epidemiology of non-Hodgkin lymphoma prognosis and prevention
|
5R01CA166219-02
|
$625,398
|
Wang, Sophia
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Evaluating New Targets of CMV Cellular Immunity
|
5R01CA145207-08
|
$369,551
|
Zaia, John
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Cold Spring Harbor Laboratory Cancer Research Center
|
5P01CA013106-42
|
$4,101,060
|
Hannon, Gregory
|
COLD SPRING HARBOR LABORATORY
|
|
CSHL CANCER CENTER SUPPORT GRANT
|
5P30CA045508-26
|
$4,077,038
|
STILLMAN, BRUCE
|
COLD SPRING HARBOR LABORATORY
|
|
Roles and regulation of p53
|
5P01CA087497-13
|
$1,668,166
|
Prives, Carol
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
|
Enhancing the vaccinal effect of antitumor antibodies
|
5R01CA164309-02
|
$312,080
|
Clynes, Raphael
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|